Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
4(27%)
Results Posted
113%(9 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_2
4
27%
Ph phase_3
11
73%

Phase Distribution

0

Early Stage

4

Mid Stage

11

Late Stage

Phase Distribution15 total trials
Phase 2Efficacy & side effects
4(26.7%)
Phase 3Large-scale testing
11(73.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

4

trials recruiting

Total Trials

15

all time

Status Distribution
Active(4)
Completed(8)
Terminated(3)

Detailed Status

Completed8
Active, not recruiting3
Withdrawn2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
4
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (26.7%)
Phase 311 (73.3%)

Trials by Status

recruiting17%
completed853%
terminated17%
withdrawn213%
active_not_recruiting320%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT03345823Phase 3

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Active Not Recruiting
NCT04161898Phase 3

A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)

Active Not Recruiting
NCT03607422Phase 3

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

Completed
NCT06928272Phase 3

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

Recruiting
NCT03569293Phase 3

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

Completed
NCT02629159Phase 3

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Active Not Recruiting
NCT04451772Phase 2

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

Completed
NCT06390722Phase 3

A Study to Assess the Effect of Upadacitinib in Atopic Dermatitis-induced Sleep Disturbance in Adults With Moderate to Severe Atopic Dermatitis

Withdrawn
NCT03086343Phase 3

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Completed
NCT03978520Phase 2

A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Completed
NCT03661138Phase 3

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
NCT03345849Phase 3

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Completed
NCT03823378Phase 2

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Terminated
NCT03682705Phase 2

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Completed
NCT04666675Phase 3

A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil

Withdrawn

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15